Cepheid Plans Assay Expansion Beyond HAI Market, Additional Sales Hires Later This Year | GenomeWeb
This story originally appeared in Biocommerce Week, a newsletter that has been discontinued.
 
Cepheid officials said last week that the firm has devised a five-year plan for assay development that will take it beyond its current focus on hospital-acquired infections and into other infectious diseases and oncology.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.